Novel approaches to the treatment of chronic graft-versus-host disease

Expert Opinion on Investigational Drugs

Volumn 10, Issue 5, 2001, Pages 909-923

  Gaziev, D ^a   Lucarelli, G ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Bone marrow transplantation; Chronic graft versus host disease; Clofazimine; Cyclophenile; Etretinate; Halofunginone; Hydroxycloroquine; IL 12 encoding plasmid; Mycophenolate mofetil; Nedocromil sodium; Oral tolerance penicillamine; Photochemotherapy; Tacrolimus; Thalidomide; Total lymphoid irradiation; Ursodeoxycholic acid

Indexed keywords

ALKALOID; AZATHIOPRINE; CLOFAZIMINE; COBALT 60; COTRIMOXAZOLE; CYCLOPHENILE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DNA; ESTROGEN DERIVATIVE; ETRETINATE; GAMMA INTERFERON; GANCICLOVIR; HALOFUNGINONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INTERLEUKIN 12; MEPREDNISONE; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEDOCROMIL SODIUM; PENICILLAMINE; PENICILLIN V; PREDNISONE; STEROID; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; GASTROINTESTINAL TOXICITY; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LYMPH NODE IRRADIATION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHOTOCHEMOTHERAPY; PROPHYLAXIS; PUVA; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SALVAGE THERAPY; SEDATION; SIDE EFFECT; SURVIVAL;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; LYMPHOID TISSUE; MYCOPHENOLIC ACID; PHOTOCHEMOTHERAPY; TACROLIMUS; THALIDOMIDE;

EID: 0035002044     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.5.909     Document Type: Review

References (119)

1. Graft-versus-host disease. Review
2. Chronic graft-versus-host disease. Review
3. Bone marrow transplantation in patients with thalassemia
4. Graft versus-host disease after bone marrow transplantation for thalassemia: An analysis of incidence and risk factors
5. Chronic graft-versus-host syndrome in man: A clinicopathological study of 20 long-term Seattle patients
6. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
7. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies
8. Chronic graft-versus-host disease (GVHD) following unrelated donor transplantation
9. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
10. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
11. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation
12. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation
13. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression
14. De novo chronic graft-versus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplant
15. Nephrotic syndrome in a bone marrow transplant recipient with chronic graft-versus-host disease
16. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation
17. A three or more drug combination as an effective therapy for moderate or severe chronic graft versus-host disease
18. The effect of thymic function on immunocompetence following bone marrow transplantation
19. Evaluation of presence and functional activity of potentially self-reactive T cells in aged mice
20. Chronic graft-versus-host disease
21. Chronic graft-versus-host disease: Is there an alternative to the conventional treatment? Review
22. Alternating-day cyclosporine and prednisolone for treatment of high-risk chronic graft-v-host disease
23. Comparison of cyclosporine (CSP), prednisone (PRED) or alternating-day CSP/PRED in patients with standard and high risk chronic graft-versus-host disease (GVHD)
24. Results of four regimens of salvage treatment of refractory chronic-graft-versus-host disease (GVHD)
25. Thalidomide in the treatment of lepra reactions
26. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
27. The immunosuppressive drug thalidomide induces T helper cell Type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures
28. Immunosuppressive properties of thalidomide
29. Thalidomide induces imbalances in T-lymphocyte subpopulations in the circulating blood of healthy males
30. Thalidomide treatment for chronic graft-versus-host disease
31. Thalidomide for the treatment of chronic graft-versus-host disease
32. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation
33. Thalidomide as salvage therapy for chronic graft-versus-host disease
34. The potential use of thalidomide in the therapy of graft-versus-host disease- a review of clinical and laboratory information
35. PUVA therapy for drug-resistant graft-versus-host disease
36. Photochemotherapy improves chronic cutaneous graft-versus-host disease
37. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease
38. PUVA therapy for chronic cutaneous graft-versus-host disease
39. Phototherapy in the treatment of cutaneous graft-versus-host disease
40. Photochemistry and photobiology of psoralens
41. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T cell lymphoma. Relevance to mechanism of action
42. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA)
43. PUVA and cancer risk: The Swedish follow-up study
44. Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft-versus-host disease
45. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: Preliminary result
46. Review of immunomodulation by photopheresis: Treatment of cutaneous T-cell lymphoma, autoimmune disease and graft rejection
47. Successful treatment of heart transplant rejection with photopheresis
48. Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes
49. Photopheresis: Clinical applications and mechanisms of action
50. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial
51. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis
52. Extracorporeal photopheresis as single therapy for extensive, cutaneous, chronic graft-versus-host disease
53. Complete remission of lichenplanus-like graft-versus-host disease (GVHD) with extracorporeal photochemotherapy (ECP)
54. Treatment of graft-versus-host disease by extracorporeal photochemotherapy
55. Adjunctive treatment of resistant chronic graft versus host disease with extracorporeal photopheresis. Using UVADEX R steril solution
56. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease
57. Extracorporeal photochemotherapy in the treatment of severe graft-versus-host disease
58. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD)
59. Extracorporeal photopheresis (EP) is effective treatment for chronic refractory graft-versus-host disease (GvHD)
60. Extracorporeal photopheresis permits steroid withdrawal in steroid-resistant chronic graft-versus-host disease
61. Discovery of FK-506 a novel immunosuppressant isolated from Streptomyces tsukubaensis
62. FK506: Historical perspectives
63. Immunosuppression and immunophilin ligands: Cyclosporin A, FK-506 and rapamycin
64. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation
65. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation
66. FK506 rescue in chronic graft-versus-host disease after bone marrow transplantation
67. FK 506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants
68. Transplantation tolerance in adult rats using total lymphoid irradiation: Permanent survival of skin, heart and marrow allografts
69. Efficacy of total lymphoid irradiation in intracTable rheumatoid arthritis
70. Low-dose (one Gray) total lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease
71. Total lymphoid irradiation for treatment of drug resistant chronic GVHD
72. Low dose thoraco-abdominal irradiation for treatment of advanced chronic graft-versus-host disease
73. Immunosuppressive treatment with 1Gy lymphoid irradiation for treatment of severe chronic graft-versus-host disease
74. Mycophenolate mofetil (drug profile)
75. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation
76. Inhibition of early chronic rejection in rat aortic allografts by mycophenolate mofetil (RS61443)
77. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
78. Mycophenolate mofetil for the treatment of acute and chronic GvHD in bone marrow transplant patients
79. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host disease (GVHD) after allogeneic hematopoietic transplantation (HSCT): Safety analysis
80. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
81. Salvage therapy with mycophenolate mofetil (MMF) for patients with severe chronic GvHD)
82. Mycophenolate mofetil (MMF) for the treatment of chronic graft versus host disease (cGVHD) of the liver
83. Clinical pharmacokinetics of clofazimine
84. Clofazimine in the treatment of discoid lupus erythematosus
85. Clofazimine in the treatment of annular lupus erythematosus
86. Treatment of pustular psoriasis with clofazimine
87. Treatment of chronic graft-versus-host disease with clofazimine
88. Acitretin and etretinate: How and when they should be used
89. Treatment of localized scleroderma and lichen sclerosus with etretinate
90. Tretinoin for the treatment of cutaneous graft-versus-host disease
91. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease
92. Mechanism of action of hydroxychloroquine as an anti-rheumatic drug
93. Antimalarial agents and lupus
94. The lysosomotropic amines, chloroquine and hydroxychloroquine: A potentially novel therapy for graft-versus-host disease
95. Hydroxychloroquine for the treatment of chronic graft-versus-host disease
96. Ursodeoxycholic acid in primary cirrhosis: Results of a controlled, double-blind trial
97. A multicenter, controlled trial of ursodiol for treatment of primary cirrhosis
98. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid
99. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver
100. Successful treatment of chronic cutaneous graft-versus-host-disease (GVHD) with penicillamine
101. Cyclophenile in 9 cases of severe sclerotic chGVHD of the skin
102. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: Effect of halofunginone
103. Topical treatment of cutaneous chronic graft versus host disease with halofunginone. A novel inhibitor of collagen Type I synthesis
104. Infection in bone marrow transplant recipients
105. Immunomodulation in allogeneic marrow transplantation: Use of intravenous immune globulin to suppress acute graft-versus-host disease
106. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-versus-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery
107. The kinetics of immune reconstitution after human marrow transplant
108. Functional asplenia after bone marrow transplantation: A late complication related to extensive chronic graft versus host disease
109. Chronic graft-versus-host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants
110. Fatal pneumococcal infections following allogeneic bone marrow transplantation
111. Reimmunization after blood or marrow stem cell transplantation
112. Long-term cyclosporine therapy may decrease the risk of chronic graft-versus-host disease
113. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
114. Mast cell 'disappearance' in chronic murine graft-versus-host disease (GVHD)-ultrastructural demonstration of 'phanton' mast cells
115. Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease
116. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
117. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice
118. IL-12 stimulates the development of acute graft-versus-host disease
119. Administration of an IL-12-encodingDNA plasmid prevents the development of chronic graft-versus-host disease